Goodwin Procter, Foley Hoag, Honigman, and Wilson Sonsini Goodrich & Rosati have advised Prime Medicine Inc. on the offering, and Paul Hastings has advised the underwriters....
Prime Medicine Closes $144 Million Public Offering of Common Stock
Prime Medicine’s $161.0 Million Common Stock Offering
Goodwin Procter advised Prime Medicine and Wilson Sonsini Goodrich & Rosati advised Prime Medicine on IP matters related to the transaction, while Davis Polk & Wardwell...
Fractyl Health’s $110 Million Initial Public Offering
Latham & Watkins and Wilson Sonsini Goodrich & Rosati advised Fractyl Health on the transaction, and Goodwin Procter advised the underwriters. Fractyl Health (Nasdaq: GUTS) announced the...
Verve Therapeutics’ Relationship Expansion with Lilly
Wilson Sonsini Goodrich & Rosati advised Verve Therapeutics on IP matters related to the transaction. Verve Therapeutics, Inc. (Nasdaq:VERV) announced the expansion of its relationship with Eli Lilly...
Azurity Pharmaceuticals’ Acquisition of Slayback Pharma
White & Case and Wilson Sonsini Goodrich & Rosati advised Azurity Pharmaceuticals, Inc., and Kirkland & Ellis advised Slayback Pharma LLC on the transaction. Azurity Pharmaceuticals,...
Verve Therapeutics’ Collaboration Agreement with Lilly
Wilson Sonsini Goodrich & Rosati advised Verve on IP matters related to the transaction. Verve Therapeutics, Inc., a clinical-stage genetic medicines company, announced an exclusive research collaboration...
Prime Medicine’s $175 Million IPO
Wilson Sonsini and Honigman advised Prime Medicine on the deal, while Davis Polk advised the joint book-running managers. Prime Medicine, Inc., a biotechnology company committed to...
Verve Therapeutics’ $225 Million Shares Public Offering
Wilson Sonsini Goodrich & Rosati advised Verve Therapeutics on the deal. Verve Therapeutics, a biotechnology company pioneering a new approach to the care of cardiovascular disease...
Azurity’s Acquisition of Arbor Pharmaceuticals
Wilson Sonsini Goodrich & Rosati and Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan advised Azurity on the deal while King & Spalding represented Arbor Pharmaceuticals. Azurity...
AbSci’s Acquisition of Totient
Wilson Sonsini Goodrich & Rosati advised Totient on the deal. AbSci, the synthetic biology company unlocking the potential of proteins as next-generation therapeutics, announced the acquisition...
Graphite Bio’s $238 Million Initial Public Offering
Wilson Sonsini Goodrich & Rosati and Goodwin Procter advised Graphite Bio on the deal. Graphite Bio, Inc., a clinical-stage, next-generation gene editing company focused on therapies...
Verve Therapeutics’ $306 Million IPO
Wilson Sonsini Goodrich & Rosati advised Verve Therapeutics on the deal. Verve Therapeutics (Nasdaq: VERV), a biotech company pioneering a new approach to the care of...